{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:39Z","timestamp":1786986939721,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.cllc.2022.12.013","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T02:20:15Z","timestamp":1674267615000},"page":"287-294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["The Association of Improved Overall Survival with NSAIDs in Non\u2013Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3977-7867","authenticated-orcid":false,"given":"Nikhil T.","family":"Sebastian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhusmita","family":"Behera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Gutman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidula","family":"Sukhatme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh S.","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas P.","family":"Sukhatme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Moghanaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2022.12.013_bib0001","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.1016\/j.cllc.2022.12.013_bib0002","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lungcan.2019.05.029","article-title":"Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis","volume":"134","author":"Dafni","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2022.12.013_bib0003","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.cllc.2022.12.013_bib0004","article-title":"The Resistance Mechanisms of Lung Cancer Immunotherapy","volume":"10","author":"Wang","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.cllc.2022.12.013_bib0005","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","article-title":"Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity","volume":"162","author":"Zelenay","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.cllc.2022.12.013_bib0006","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12967-017-1150-7","article-title":"COX-2 expression positively correlates with PD-L1 expression in human melanoma cells","volume":"15","author":"Botti","year":"2017","journal-title":"Journal of Translational Medicine"},{"key":"10.1016\/j.cllc.2022.12.013_bib0007","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1158\/1940-6207.CAPR-18-0087","article-title":"Aspirin Suppresses PGE2 and Activates AMP Kinase to Inhibit Melanoma Cell Motility, Pigmentation, and Selective Tumor Growth In Vivo","volume":"11","author":"Kumar","year":"2018","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.cllc.2022.12.013_bib0008","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.cllc.2022.12.013_bib0009","first-page":"36","article-title":"Combination therapy of PKC\u03b6 and COX-2 inhibitors synergistically suppress melanoma metastasis","author":"Zhou","year":"2017","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.1016\/j.cllc.2022.12.013_bib0010","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/cas.12852","article-title":"Timosaponin AIII inhibits melanoma cell migration by suppressing COX -2 and in vivo tumor metastasis","volume":"107","author":"Kim","year":"2016","journal-title":"Cancer Science"},{"key":"10.1016\/j.cllc.2022.12.013_bib0011","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1097\/CMR.0000000000000291","article-title":"In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine","volume":"26","author":"Sadhu","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.cllc.2022.12.013_bib0012","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1074374","article-title":"Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity","volume":"5","author":"Li","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.cllc.2022.12.013_bib0013","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1073\/pnas.1612920114","article-title":"COX2\/mPGES1\/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells","volume":"114","author":"Prima","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cllc.2022.12.013_bib0014","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.2174\/0929867325666180514112124","article-title":"Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases","volume":"26","author":"Ferrer","year":"2019","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.cllc.2022.12.013_bib0015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12885-020-06882-6","article-title":"Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications","volume":"20","author":"Spakowicz","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2022.12.013_bib0016","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.3390\/cells11162505","article-title":"Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma","volume":"11","author":"Zhang","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.cllc.2022.12.013_bib0017","article-title":"Effect of Concomitant Use of Analgesics on Prognosis in Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"13","author":"Mao","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cllc.2022.12.013_bib0018","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0518","article-title":"The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma","volume":"25","author":"Wang","year":"2020","journal-title":"The Oncologist"},{"key":"10.1016\/j.cllc.2022.12.013_bib0019","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/imt-2019-0064","article-title":"Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors","volume":"12","author":"Gandhi","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.cllc.2022.12.013_bib0020","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.celrep.2019.08.068","article-title":"Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy","volume":"29","author":"Renner","year":"2019","journal-title":"Cell Reports"},{"key":"10.1016\/j.cllc.2022.12.013_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.688485","article-title":"Lactate Is a Metabolic Mediator That Shapes Immune Cell Fate and Function","volume":"12","author":"Caslin","year":"2021","journal-title":"Front Physiol"},{"key":"10.1016\/j.cllc.2022.12.013_bib0022","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/ijc.27712","article-title":"Diclofenac inhibits lactate formation and efficiently counteracts local immune suppression in a murine glioma model","volume":"132","author":"Chirasani","year":"2013","journal-title":"International journal of cancer"},{"key":"10.1016\/j.cllc.2022.12.013_bib0023","first-page":"610","article-title":"Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent","volume":"10","author":"Pantziarka","year":"2016","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.cllc.2022.12.013_bib0024","doi-asserted-by":"crossref","first-page":"e12715","DOI":"10.1371\/journal.pone.0012715","article-title":"Diclofenac Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer by Modulation of VEGF Levels and Arginase Activity","volume":"5","author":"Mayorek","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cllc.2022.12.013_bib0025","doi-asserted-by":"crossref","DOI":"10.3892\/etm.2021.10016","article-title":"Diclofenac impairs the proliferation and glucose metabolism of triple\u2011negative breast cancer cells by targeting the c\u2011Myc pathway","volume":"21","author":"Yang","year":"2021","journal-title":"Experimental and Therapeutic Medicine"},{"key":"10.1016\/j.cllc.2022.12.013_bib0026","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1080\/13102818.2021.1953401","article-title":"Cytotoxic and antiproliferative effects of the nonsteroidal anti-inflammatory drug diclofenac in human tumour cell lines","volume":"35","author":"Marinov","year":"2021","journal-title":"Biotechnology & Biotechnological Equipment"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423000013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423000013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:20Z","timestamp":1761506060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730423000013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1525730423000013"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2022.12.013","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Association of Improved Overall Survival with NSAIDs in Non\u2013Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2022.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}